Shuichiro Iwasaki

Sagamihara, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Reply to Comment on Randomized Controlled Trial of Endoscopic Ultrasound-Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens.

Reply to Comment on Randomized Controlled Trial of Endoscopic Ultrasound-Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens.

Journal: Journal of gastroenterology and hepatology

Published: August 13, 2026

Reply to "Methodological Concerns Regarding the Primary Endpoint and External Validity in the Randomized Trial of EUS-Guided Versus Percutaneous Liver Biopsy".

Reply to "Methodological Concerns Regarding the Primary Endpoint and External Validity in the Randomized Trial of EUS-Guided Versus Percutaneous Liver Biopsy".

Journal: Journal of gastroenterology and hepatology

Published: July 30, 2026

Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety.

Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety.

Journal: Cancers

Published: July 26, 2026

Statin Use Is Associated With Improved Survival But Not Progression-Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab.

Statin Use Is Associated With Improved Survival But Not Progression-Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 19, 2026

Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.

Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.

Journal: Alimentary pharmacology & therapeutics

Published: January 25, 2026

A Prospective Observational Study of AUDIT-based Risk Stratification and Drinking Guidance Provided by Hepatologists in Patients with Alcoholic Liver Disease.

A Prospective Observational Study of AUDIT-based Risk Stratification and Drinking Guidance Provided by Hepatologists in Patients with Alcoholic Liver Disease.

Journal: Internal medicine (Tokyo, Japan)

Published: January 14, 2026

Randomized Controlled Trial of Endoscopic Ultrasound-Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens.

Randomized Controlled Trial of Endoscopic Ultrasound-Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens.

Journal: Journal of gastroenterology and hepatology

Published: October 10, 2025

Endoscopic ultrasound-guided cyanoacrylate injection for jejunal varices at the hepaticojejunostomy site using a forward-viewing echoendoscope.

Endoscopic ultrasound-guided cyanoacrylate injection for jejunal varices at the hepaticojejunostomy site using a forward-viewing echoendoscope.

Journal: Clinical endoscopy

Published: September 03, 2025

Digital Polymerase Chain Reaction-Based Fecal Streptococcus Quantification for Liver Fibrosis Assessment in Chronic Liver Disease.

Digital Polymerase Chain Reaction-Based Fecal Streptococcus Quantification for Liver Fibrosis Assessment in Chronic Liver Disease.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 30, 2025

Quantification of Streptococcus salivarius using the digital polymerase chain reaction as a liver fibrosis marker.

Quantification of Streptococcus salivarius using the digital polymerase chain reaction as a liver fibrosis marker.

Journal: World journal of hepatology

Published: October 06, 2024

A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.

A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.

Journal: Clinical journal of gastroenterology

Published: June 05, 2024

Esophageal Varices as an Independent Predictor of Fatal Outcomes after Balloon-Occluded Retrograde Transvenous Obliteration in Patients with Hepatic Encephalopathy.

Esophageal Varices as an Independent Predictor of Fatal Outcomes after Balloon-Occluded Retrograde Transvenous Obliteration in Patients with Hepatic Encephalopathy.

Journal: Digestive diseases (Basel, Switzerland)

Published: May 12, 2024

Showing 1-12 of 25

Last Updated: 09/26/2026